CN1087616C - Medicine for treating hepatism - Google Patents
Medicine for treating hepatism Download PDFInfo
- Publication number
- CN1087616C CN1087616C CN98117279A CN98117279A CN1087616C CN 1087616 C CN1087616 C CN 1087616C CN 98117279 A CN98117279 A CN 98117279A CN 98117279 A CN98117279 A CN 98117279A CN 1087616 C CN1087616 C CN 1087616C
- Authority
- CN
- China
- Prior art keywords
- parts
- amino acid
- present
- medicine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to medicine for treating hepatopathy, which is prepared by taking compound amino acid, astragalus root, matrimony vine, tangshen, red sage root, Chinese date and cane sugar as raw materials in a normal preparation technology. The present invention adopts 18 kinds of amino acid, regulates the ratio of high branched chain amino acid and low aromatic amino acid, fully contains high branched chain amino acid, and is added with Chinese medicinal materials for treating hepatopathy to cause the components to be more reasonable. Compared with import medicine, the present invention with the advantage of low cost can provide enough heat quantity, avoid the decomposition of muscle protein, promote the synthesis and staggered reverse of the protein in vivo, and increase the regeneration and functions of liver cells. When the present invention is used for treating different kinds of hepatopath, the effect is satisfactory.
Description
The present invention relates to a kind of medicine for the treatment of hepatopathy, specifically a kind of is the medicine that material combination is made with aminoacids complex (being rich in branched-chain amino acid) with Chinese medicine, is applicable to viral hepatitis, alcoholic hepatitis, the treatment of drug induced hepatic injury etc.
At present, the amino acid therapy of hepatopathy is more and more paid attention to for people.At first propose the infull patient of liver function from Fischer the seventies, particularly hepatic encephalopathy patient Proteometabolism is unusual, is that (SURGERY 1975 for the main cause that causes hepatic coma so that cause the blood plasma amino acid imbalance; 73:276).Its viewpoint is that the change of blood plasma aminogram makes interior ArAA of brain and methionine increase and form false neurotransmitter and causes stupor to take place.Based on this theory, and for energy is provided, nutrition and reparation and promote proteinic syntheticly and are manufactured experimently out Freamine (Fischer liquid: F0-80, homemade liver peace by name), the amino acid imbalance when being used to correct hepatic encephalopathy and occurring.
Now be used for hepatopath's products of amino acid abroad, all contain higher branched-chain amino acid, and aromatic amino acid be lower, in order to generation and the doing well,improving that prevents hepatic encephalopathy.Said products costs an arm and a leg, the liver ammonia of making as import drugs looses, and this quasi drugs only contains bright, and is different bright, three kinds of branched-chain amino acid such as figured silk fabrics, and do not contain all the other tens seed amino acids, even the imitative special liver of hepatopathy is pacified 8% injection, still lack necessary aminoacid (egg, phenylpropyl alcohol and color), therefore all belong to unbalanced amino acid preparation, what be only applicable to hepatic encephalopathy stress patient.
The objective of the invention is to: based on hepatopath's vivo acid metabolic balance theory, adjust higher branched-chain amino acid and lower aromatic amino acid ratio according to the hepatopathy characteristics, and be equipped with Chinese medicine, make its various compositions more reasonable, and a kind of medicine for the treatment of hepatopathy is provided, adjust organism metabolism balance, enhancing human body immunity power, alleviate burden of liver being intended to.
Medicine of the present invention is made (consumption is a weight portion) by following component:
Aminoacids complex 10-20 part, Radix Astragali 10-20 part, Fructus Lycii 10-20 part, Radix Codonopsis 5-20 part, Radix Salviae Miltiorrhizae 10-20 part, Fructus Jujubae 10-20 part, sucrose 1-10 part.
Wherein aminoacids complex is formed by following weight portion: aspartic acid 2.32-5.31 part, glycine 5.00-7.25 part, methionine 2.35-5.35 part, threonine 3.15-5.15 part, alanine 5.31-9.21 part, serine 2.57-3.98 part, isoleucine 9.00-14.32 part, cystine 0.15-0.72 part, leucine 8.32-15.32 part, glutamic acid 4.32-10.28 part, valine 8.32-16.31 part, tyrosine 0.15-0.32 part, phenylalanine 0.87-3.17 part, arginine 1.32-3.25 part, lysine 4.11-8.11 part, proline-4 .21-10.15 part, histidine 0.85-1.85 part, tryptophan 0.21-1.32 part.
The optimum weight proportioning of medicine of the present invention is:
11 parts of aminoacids complexs, 14 parts of the Radixs Astragali, 14 parts of Fructus Lyciis, 9 parts of Radix Codonopsis, 16 parts of Radix Salviae Miltiorrhizaes, 16 parts in Fructus Jujubae, 3 parts of sucrose.
Wherein aminoacids complex is formed by following weight portion: 4.46 parts of aspartic acids, 6.38 parts of glycine, 3.21 parts of methionine, 4.15 parts of threonine, 8.11 parts of alanine, 3.17 parts of serines, 12.99 parts of isoleucine, 0.63 part of cystine, 13.87 parts of leucines, 8.30 parts in glutamic acid, 12.23 parts of valines, 0.23 part in tyrosine, 2.07 parts of phenylalanine, arginase 12 .58 part, 6.11 parts of lysines, 5.64 parts of proline, 1.07 parts of histidine, 0.77 part of tryptophan.
Above-mentioned each component is made medicine production technology of the present invention all adopt conventional manufacture method preparation.
The present invention and F0-80 liquid phase ratio contain branched-chain amino acid, and the former accounts for 40.81% of total amino acids, and the latter accounts for 33.88%; Contain aromatic amino acid, the former is 3.2%, latter position 2.1%.And the former also contains all the other tens seed amino acids, sees table five for details.
Experimentation of the present invention: with the rat acute hepatic injury due to the galactosamine is animal model, raise with the present invention, and with liver ammonia loose (Tianjin pharmacy two factories of central authorities) compare, observe symptom, survival, liver function and the amino acid whose variation respectively organized before and after the rat experiment.
Material and method: with the rat of selecting for use, body weight 200-300 gram is divided into four groups at random, and each organizes 30, and experimental group A organizes (raising with the present invention), B group (raise with liver ammonia and loose), and C organizes (raising with common food), and D organizes (intraperitoneal injection of saline).Raised back 24 hours, and got 10 blood samplings for every group, survey serum glutamic pyruvic transminase, aminoacid, protein content.All the other continue to observe death and symptom.
The experimental result symptom: the injection galactosamine is after 24 hours, and it is not too obvious that each organizes symptom, beginning in about 38 hours, and each organizes the symptom that drowsiness and similar stupor in various degree appears in rat, and increases the weight of in time.Death (survival) as shown in Table 1.
Changes of liver function: the injection galactosamine is after 24 hours, and the Serum ALT value obviously raises (except the blank group), and As time goes on, different variation such as table two appear in each lab A LT value, shown in the table three.
Each organizes the variation of rat blood serum aminogram: each organizes rat in the variation of injecting 24 hours later blood sampling analysis of amino acid content of galactosamine as shown in Table 4.
, survive from symptom by above result: the A group of respectively organizing, changes of liver function, serum amino acid props up/fragrant ratio, all is better than the C group, and similar with the B group.
For showing the therapeutic effect of medicine of the present invention to hepatopathy, the present invention selects 50 routine patients to carry out clinical experiment in three tame hospitals, male's 29 examples wherein, women's 21 examples, the oldest 78 years old, minimum 24 years old.2 examples more than 20 years old, 14 examples more than 30 years old, 14 examples more than 40 years old, 10 examples more than 50 years old, 10 examples more than 60 years old.
Diagnostic criteria Western medicine diagnose standard, symptom is: feel sick, detest greasyly, diet is poor, abdominal distention, pain in the hepatic region, weak, become thin, hepatic facies, liver palm, splenomegaly or promptly toward history of virus hepatitis, existing obviously sick; Laboratory inspection: abnormal liver function, B ultrasonic is unusual.The tcm diagnosis standard, symptom is: weak, become thin, feel sick and detest oil, the abdominal distention loose stool, anorexia, right rib is pain down, hepatic facies.
MethodsThe cases enrolled standard: all abnormal liver function or promptly toward having hepatitis history or primary symptom that five above persons are arranged.
Instructions of taking: oral, each one bag, every day three times.
Curative effect determinate standard symptom curative effect produce effects: after taking one month continuously, transference cure is more than 2/3rds; Effectively: after taking one month continuously, transference cure is more than 1/3rd; The laboratory is checked: liver function recovery normally is a produce effects, transfers to well effectively.
Through clinical 50 routine result on trial, produce effects 33 examples account for sum 66%; Effective 17 examples account for sum 34%.Clinical observation shows, safety of the present invention effectively, has no side effect, taking convenience, and patient's symptom curative effect and feeling takes a turn for the better obviously.The embodiment of the invention: aminoacids complex when making granule, earlier with Chinese crude drug-lixiviate-separation-concentrated-spray drying, then is mixed into the granule pack with aminoacid powder for directly buying; When making oral liquid, operation is Chinese crude drug decoction-filtration, with aminoacid powder miscible-filtration-bottling (10 milliliters every bottle)-sterilization-packing.
Table one: each organizes the survival of rats situation
The 3rd day the 4th day A group of first day second day (30) 20 (adopt 10 17 11 11
Only) B group (30) 20 (adopt 10 18 10 10
Only) C group (30) 20 (adopt 10 16 80
Only) D group (30) 20 (adopt 10 20 20 20
Only)
Table two: each organizes the rat blood serum liver function
A group B group C group D group ALT 178 ± 42 224 ± 70 325 ± 65 19 ± 5.6
P＜0.01 P＜0.05 P＜0.001
TP 46.2±8.5 38.8±7.2 31.7±8.2 58.4±4.2
P＜0.05 P＞0.05 P＜0.001
ALB 39.2±3.2 30.1±4.0 26.4±2.1 42.4±3.2
P＜0.05 P＜0.05 P＜0.01
Table three: each organizes over time n=10 of rat blood serum liver function
ALT TP ALB
The one the second the three the one the second the three the one the second three
Everyday the sky everyday A organize 162 153 32 ± 44 ± 39.2 31.2 32.1 35.1 24.2
±45 ±42 15 35 ±18 ±18 ±19 ±20 ±13
P＜0. P＜0. P＜0. P＞0. P＞0. P＞0. P＞0. P＞0. P＞0.
01 01 01 05 05 05 05 05 05 B organize 200 215 21 ± 36 ± 37.2 62.1 35.5 33.4 31.1
±78 ±34 20 16 ±25 ±25 ±28 ±22 ±17
P＜0. P＜0. P＜0. P＞0. P＞0. P＜0. P＞0. P＞0. P＞0.
05 05 01 05 05 01 05 05 05C organize 362 413 239 38.4 19.2 18.4 35.4 39.1 25.1
± ± ± ±27 ±18 ±18 ±15 ±8 ±19
185 145 102D group 17 ± 27 ± 28 ± 58.1 42.1 52.2 42.9 48.9 49.1
15 20 15 ±18 ±25 ±20 ±25 ±21 ±25
P＜0. P＜0. P＜0. P＞0. P＞0. P＜0. P＞0. P＞0. P＞0.
01 01 01 05 05 01 05 05 05
Table four: each organize rat blood serum aminogram n=10 aminoacid title A group B group C group D group taurine 269.9 ± 194.5 ± 212 ± 23.9 151.5 ±
29.5 38.5 18.5 aspartic acid 28.5 ± 3.1 20.7 ± 9.6 28.1 ± 11.3 21.9 ± 9.6 threonine 642.6 ± 642 ± 291 531.6 ± 366.4 ±
121.3 60.7 38.7 serine 153.3 ± 154.5 ± 133 ± 20.8 107.4 ±
25.5 70.5 42.2 glutamic acid 182 ± 10.4 171.5 ± 158 ± 16.4 98.6 ± 17.8
47.5 glycine 321 ± 55.8 298 ± 134 229.3 ± 184.7 ±
31.8 32.4 alanine 339.3 ± 336.5 ± 254.6 ± 200.3 ±
85.5 164.5 47.4 40.2 cystines 52.3 ± 13.1 28.9 ± 10.7 29.3 ± 11.0 14.1 ± 10.2 valines 108 ± 11.4 86.4 ± 36.4 77.0 ± 2.9 79.1 ± 3.1 methionine 471 ± 7.5 38.5 ± 11.5 32.8 ± 3.9 28.2 ± 4.2 isoleucine 51.2 ± 5.8 38.9 ± 16.3 38.7 ± 1.8 37.9 ± 1.0 leucine 108.9 ± 89.2 ± 41.8 83.8 ± 6.1 87.4 ± 5.3
10.7 tyrosine 63.9 ± 10.5 43.2 ± 10.9 85.8 ± 0.7 24 ± 1.4 phenylalanine 42.7 ± 2.8 38.7 ± 8.2 71.9 ± 10.6 34.9 ± 8.9 ornithine 107.6 ± 5.9 87.3 ± 34.6 78 ± 13.6 25.8 ± 12.1 lysine 146.7 ± 171.1 ± 130 ± 46.1 172.3 ±
32.3 123.9 32.8 histidines 44.2 ± 11.3 32.5 ± 9.1 36.4 ± 0.7 27.0 ± 1.8 tryptophan 40.1 ± 3.9 56.9 ± 9.5 48.3 ± 6.1 42.7 ± 7.8 arginine 9.8 ± 7.7 5.6 ± 5.6 46.2 ± 49 83.8 ± 32 proline 106.7 ± 106.3 ± 107 ± 48.2 155.9 ±
27.3 37.8 42.3BCAA/AAA 2.5±0.04 2.5±0.6 1.3±0.3 3.5±0.8
P＜0.001 P＜0.01 P＜0.01
The P value is propped up/fragrant ratio and C group comparative result for each group rat plasma aminoacid
Table five: the aminoacid of the present invention and F0-80 liquid is formed content relatively
F0-80 liquid (%) the present invention (%) isoleucine 10.74 13.56 leucines 13.12 14.48 valines 10.02 12.27BCAA 33.88 40.81 phenylalanines 1.19 2.16 tyrosine 0.24 tryptophan 0.91 0.80AAA 2.10 3.20BCAA/AAA 3.80 20.00
Claims (2)
1 one kinds of medicines for the treatment of hepatopathy is characterized in that it is to make by following materials of weight proportions: aminoacids complex 10-20 part, Radix Astragali 10-20 part, Fructus Lycii 10-20 part, Radix Codonopsis 5-20 part, Radix Salviae Miltiorrhizae 10-20 part, Fructus Jujubae 10-20 part, sucrose 1-10 part;
Wherein aminoacids complex is formed by following weight proportion: aspartic acid 2.32-5.31 part, glycine 5.00-7.25 part, methionine 2.35-5.35 part, threonine 3.15-5.15 part, alanine 5.31-9.21 part, serine 2.57-3.98 part, isoleucine 9.00-14.32 part, cystine 0.15-0.72 part, leucine 8.32-15.32 part, glutamic acid 4.32-10.28 part, valine 8.32-16.31 part, tyrosine 0.15-0.32 part, phenylalanine 0.87-3.17 part, arginine 1.32-3.25 part, lysine 4.11-8.11 part, proline-4 .21-10.15 part, histidine 0.85-1.85 part, tryptophan 0.21-1.32 part.
The medicine of 2 treatment hepatopathys according to claim 1 is characterized in that the weight proportion of each raw material is: 11 parts of aminoacids complexs, 14 parts of the Radixs Astragali, 14 parts of Fructus Lyciis, 9 parts of Radix Codonopsis, 16 parts of Radix Salviae Miltiorrhizaes, 16 parts in Fructus Jujubae, 3 parts of sucrose;
Wherein aminoacids complex is formed by following weight proportion: 4.46 parts of aspartic acids, 6.38 parts of glycine, 3.21 parts of methionine, 4.15 parts of threonine, 8.11 parts of alanine, 3.17 parts of serines, 12.99 parts of isoleucine, 0.63 part of cystine, 13.87 parts of leucines, 8.30 parts in glutamic acid, 12.23 parts of valines, 0.23 part in tyrosine, 2.07 parts of phenylalanine, arginase 12 .58 part, 6.11 parts of lysines, 5.64 parts of proline, 1.07 parts of histidine, 0.77 part of tryptophan.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98117279A CN1087616C (en) | 1998-08-14 | 1998-08-14 | Medicine for treating hepatism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98117279A CN1087616C (en) | 1998-08-14 | 1998-08-14 | Medicine for treating hepatism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1245065A CN1245065A (en) | 2000-02-23 |
| CN1087616C true CN1087616C (en) | 2002-07-17 |
Family
ID=5225441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98117279A Expired - Fee Related CN1087616C (en) | 1998-08-14 | 1998-08-14 | Medicine for treating hepatism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1087616C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329030C (en) * | 2002-12-26 | 2007-08-01 | 味之素株式会社 | Inhibitor for liver cancer onset and progress |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2372900C2 (en) * | 2004-07-14 | 2009-11-20 | Адзиномото Ко., Инк. | Inhibitor of contraction and development of liver cancer to be applied in hepatitis c positive patients suffering from cirrhosis |
| US8197860B2 (en) | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
-
1998
- 1998-08-14 CN CN98117279A patent/CN1087616C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 广西中医药1998,21(1) 1998.1.31 中西医结合治疗肝硬化腹水83例 * |
| 广西中医药1998,21(1) 1998.1.31 中西医结合治疗肝硬化腹水83例;新药与临床1996,15(4) 1996.4.30 傅志君等，复合氨基酸和维生素治疗肝硬化低蛋白症病人的闻效 * |
| 新药与临床1996,15(4) 1996.4.30 傅志君等，复合氨基酸和维生素治疗肝硬化低蛋白症病人的闻效 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329030C (en) * | 2002-12-26 | 2007-08-01 | 味之素株式会社 | Inhibitor for liver cancer onset and progress |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1245065A (en) | 2000-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145128B (en) | Medicinal composition for preventing and treating cardiac and cerebral vascular diseases and preparation method thereof | |
| CN104623201B (en) | A kind of liver protection Elmination of toxicant and fat-lowering hypoglycemic medicine and its application | |
| CN1224691C (en) | Medical wine for invigorating vital function of kidney and its preparing process | |
| CN100339111C (en) | Medicine for treating coronary heart disease and its prepn | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN1235601C (en) | Extractive of ocean star worm, its preparing method and application | |
| CN1087616C (en) | Medicine for treating hepatism | |
| CN1899448A (en) | Chinese medicine compound preparation for treating amblyopia and its preparing method | |
| CN1178119A (en) | Traditional Chinese medicine preparation for treating senile dementia | |
| CN100342880C (en) | Oral liquid of royal jelly of ginseng and hairy antler, and preparation method | |
| CN1253786A (en) | Fresh deer's blood health-care medicated wine and its preparation method | |
| CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN1169564C (en) | New medicine for curing diobetes | |
| CN1679855A (en) | Use of astragalus root in preparing medicine for dilating blood vessel | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN1313133C (en) | Medicine composition for treating coronary heart disease and its prepn process | |
| CN1042597C (en) | Vision-brighting and blood sugar decreasing composition and its produciton | |
| CN104706813A (en) | Mulberry-glossy privet fruit health composition | |
| CN1264519C (en) | Notoginseng total saponin amino acid transfusion liquid and its producing method | |
| CN1121869C (en) | Sugar-correcting capsule | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN1823945A (en) | Chinese medicinal preparation for treating fatly liver and its preparation method | |
| CN1079658A (en) | A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease | |
| CN101066327A (en) | Functional health wine and its prepn process | |
| CN1768778A (en) | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |